tetano
Editor, Senior Moderator
Immunol Cell Biol
. 2022 Feb 21.
doi: 10.1111/imcb.12539. Online ahead of print.
The vaccinia-based Sementis Copenhagen Vector COVID-19 vaccine induces broad and durable cellular and humoral immune responses
Preethi Eldi[SUP] 1 [/SUP], Tamara H Cooper[SUP] 1 [/SUP], Natalie A Prow[SUP] 1 [/SUP], Liang Liu[SUP] 1 2 [/SUP], Gary K Heinemann[SUP] 1 [/SUP], Voueleng J Zhang[SUP] 1 [/SUP], Abigail D Trinidad[SUP] 1 [/SUP], Ruth Marian Guzman-Genuino[SUP] 3 [/SUP], Peter Wulff[SUP] 3 [/SUP], Leanne M Hobbs[SUP] 1 3 [/SUP], Kerrilyn R Diener[SUP] 1 4 [/SUP], John D Hayball[SUP] 1 3 [/SUP]
Affiliations
Abstract
The ongoing coronavirus disease (COVID-19) pandemic perpetuated by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) variants, has highlighted the continued need for broadly protective vaccines that elicit robust and durable protection. Here, the vaccinia virus-based, replication-defective Sementis Copenhagen Vector (SCV) was used to develop a first-generation COVID-19 vaccine encoding the spike glycoprotein (SCV-S). Vaccination of mice rapidly induced polyfunctional CD8 T cells with cytotoxic activity and robust Th1-biased, spike-specific neutralizing antibodies, which are significantly increased following a second vaccination, and contained neutralizing activity against the alpha and beta variants of concern. Longitudinal studies indicated neutralizing antibody activity was maintained up to 9 months post-vaccination in both young and middle-aged mice, with durable immune memory evident even in the presence of pre-existing vector immunity. Therefore, SCV-S vaccination has a positive immunogenicity profile, with potential to expand protection generated by current vaccines in a heterologous boost format and presents a solid basis for second-generation SCV-based COVID-19 vaccine candidates incorporating additional SARS-CoV-2 immunogens.
Keywords: COVID-19; SARS-CoV-2; Vaccine; antibodies; cellular responses; spike.
. 2022 Feb 21.
doi: 10.1111/imcb.12539. Online ahead of print.
The vaccinia-based Sementis Copenhagen Vector COVID-19 vaccine induces broad and durable cellular and humoral immune responses
Preethi Eldi[SUP] 1 [/SUP], Tamara H Cooper[SUP] 1 [/SUP], Natalie A Prow[SUP] 1 [/SUP], Liang Liu[SUP] 1 2 [/SUP], Gary K Heinemann[SUP] 1 [/SUP], Voueleng J Zhang[SUP] 1 [/SUP], Abigail D Trinidad[SUP] 1 [/SUP], Ruth Marian Guzman-Genuino[SUP] 3 [/SUP], Peter Wulff[SUP] 3 [/SUP], Leanne M Hobbs[SUP] 1 3 [/SUP], Kerrilyn R Diener[SUP] 1 4 [/SUP], John D Hayball[SUP] 1 3 [/SUP]
Affiliations
- PMID: 35188985
- DOI: 10.1111/imcb.12539
Abstract
The ongoing coronavirus disease (COVID-19) pandemic perpetuated by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) variants, has highlighted the continued need for broadly protective vaccines that elicit robust and durable protection. Here, the vaccinia virus-based, replication-defective Sementis Copenhagen Vector (SCV) was used to develop a first-generation COVID-19 vaccine encoding the spike glycoprotein (SCV-S). Vaccination of mice rapidly induced polyfunctional CD8 T cells with cytotoxic activity and robust Th1-biased, spike-specific neutralizing antibodies, which are significantly increased following a second vaccination, and contained neutralizing activity against the alpha and beta variants of concern. Longitudinal studies indicated neutralizing antibody activity was maintained up to 9 months post-vaccination in both young and middle-aged mice, with durable immune memory evident even in the presence of pre-existing vector immunity. Therefore, SCV-S vaccination has a positive immunogenicity profile, with potential to expand protection generated by current vaccines in a heterologous boost format and presents a solid basis for second-generation SCV-based COVID-19 vaccine candidates incorporating additional SARS-CoV-2 immunogens.
Keywords: COVID-19; SARS-CoV-2; Vaccine; antibodies; cellular responses; spike.